Table 3 Pathways with Overrepresentation of Genes Targeted by an Intronic miRNA

MAPK Signaling

ATF2; DDIT3; AKT2; FGF13; ARRB1; PPP3CA; PRKCA; CACNG8; RPS6KA2; MAP2K4; RPS6KA4

61.4%

< 0.001

< 0.001

Axon Guidance

PPP3CA; PTK2; SEMA4G; SEMA3F; SLIT3; ABLIM2; SLIT2

70.3%

< 0.001

< 0.001

Ubiquitin Mediated Proteolysis

HUWE1; WWP2; BIRC6; ITCH

53.8%

< 0.001

< 0.001

Focal Adhesion

COL3A1; AKT2; PRKCA; PTK2; TLN2

49.5%

< 0.001

< 0.001

Glioma

AKT2; PRKCA

52.3%

< 0.001

< 0.001

Melanoma

AKT2; FGF13

50.7%

< 0.001

< 0.001

Regulation of Actin Cytoskeleton

CHRM2; FGF13; SSH1; PTK2

41.0%

< 0.001

< 0.001

Chronic Myloid Leukemia

AKT2

38.2%

< 0.001

< 0.001

Colorectal Cancer

AKT2

35.7%

< 0.001

< 0.001

Prostate Cancer

AKT2

34.8%

0.001

0.007

Melanogenesis

PRKCA

21.6%

0.001

0.007

Pancreatic Cancer

AKT2

35.6%

0.002

0.01

ErbB Signaling

ERBB4; AKT2; PRKCA; PTK2; MAP2K4

51.7%

0.003

0.02

Glycan Structures Biosynthesis

MGAT4B; FUT8; CSGLCA-T; GALNT10; HS3ST3A1

50.8%

0.003

0.02

Gap Junction

HTR2C; PRKCA; PRKG1

47.9%

0.005

0.02

Non-Small Cell Lung Cancer

AKT2; PRKCA

42.6%

0.007

0.03

Small Cell Lung Cancer

AKT2; PTK2

35.6%

0.013

0.05

Long-Term Depression

PRKCA; PRKG1

33.3%

0.014

0.05

Insulin Signaling

AKT2; SREBF1

36.0%

0.014

0.05

Long-Term Potentiation

PPP3CA; PRKCA; RPS6KA2

27.1%

0.005

0.06

T-Cell Receptor Signaling

AKT2; PPP3CA

32.3%

0.016

0.09

Wnt Signaling

PPP3CA; PRKCA

21.6%

0.020

0.09